Literature DB >> 3110065

Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.

S J Cryz, A B Lang, J C Sadoff, R Germanier, E Fürer.   

Abstract

Serologically reactive O-polysaccharide from nine serotypes of Pseudomonas aeruginosa were covalently linked to toxin A via reductive amination, with adipic acid dihydrazide serving as a spacer molecule. The conjugates were composed of toxin A/O-polysaccharide ratios ranging from 1.17:1 to 3:1. All possessed an average Mr of greater than 10(6), were devoid of ADP ribosyltransferase activity associated with toxin A, and were nontoxic for mice and guinea pigs. The conjugates were stable from toxic reversion when stored at 37 degrees C for 28 days. The conjugation condition used preserved a substantial proportion of critical epitopes on the toxin A molecule as shown by the ability of toxin A-neutralizing monoclonal antibodies to react with the various conjugates. All nine conjugates were capable of evoking an antitoxin A and an antilipopolysaccharide immunoglobulin G (IgG) response in mice and rabbits. Rabbit antitoxin A IgG was capable of neutralizing the cytotoxic effect of toxin A, whereas mice immunized with any of the conjugates were protected against toxin A intoxication. Rabbit anti-conjugate IgG, when passively transferred to mice, was highly effective at preventing fatal P. aeruginosa burn wound sepsis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110065      PMCID: PMC260556          DOI: 10.1128/iai.55.7.1547-1551.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  22 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A.

Authors:  B H Iglewski; J C Sadoff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Immunization against Pseudomonas in infection after thermal injury.

Authors:  J Wesley; A Fisher; M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

7.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

8.  Analytical characterization of lipopolysaccharide antigens from seven strains of Pseudomonas aeruginosa.

Authors:  D Horton; G Rodemeyer; T H Haskell
Journal:  Carbohydr Res       Date:  1977-05       Impact factor: 2.104

9.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

10.  Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.

Authors:  K Snell; I A Holder; S A Leppla; C B Saelinger
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more
  10 in total

1.  Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

Authors:  J U Que; S J Cryz; R Ballou; E Fürer; M Gross; J Young; G F Wasserman; L A Loomis; J C Sadoff
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

2.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

5.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

7.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

Authors:  R Hertle; R Mrsny; D J Fitzgerald
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.609

9.  Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue.

Authors:  M Lukac; G B Pier; R J Collier
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.609

10.  Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity.

Authors:  Faezeh Najafzadeh; Reza Shapouri; Mehdi Rahnema; Shadi Rokhsartalab Azar; Anvarsadat Kianmehr
Journal:  Jundishapur J Microbiol       Date:  2015-06-27       Impact factor: 0.747

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.